A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
Status:
Active, not recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if the combination of buparlisib and ibrutinib will
lead to better treatment results in patients with relapsed or refractory Follicular lymphoma,
(FL) Mantle cell lymphoma (MCL) or Diffuse Large B-cell lymphoma (DLBCL). The investigators
are using buparlisib and ibrutinib because both drugs seem to block different proteins that
allow cancer cells to keep growing. Blocking these proteins may help by making the cancer
cells undergo cell death, which will stop uncontrolled tumor growth.